Effects of short (6 months) and long (18 months) term treatment with gh-receptor antagonist pegvisomant (peg) on rhythm disturbances in acromegaly
Renata Auriemma, Federico II University of Naples, Italy
Long term treatment with pegvisomant in acromegalic patients results in significant improvement in cardiac rhythm, with low incidence of adverse events
Cardiovascular risk factors in treatment-resistant, active and long-term acromegaly: comparison to matched data from the general population and the effect of disease control
Christian Berg, University Hospital of Essen, Germany
In addition to being associated with an increase risk of cardiomyopathy, patients with acromegaly also experience a significant increase in the risk of CHD.
Pegvisomant significantly reduces the risk of CV risk in acromegalic patients, particularly in patients with normalised IGF-1 levels